Reflecting on 2025, looking to 2026: Experts discuss what counts as high-value RWD, and how evidence generation is changing

In The Evidence Base, Joanne Walker looks back on how 2025 reshaped expectations for real-world evidence – and what 2026 will demand next. The article explores the shift toward decision-ready RWD, AI-enabled workflows, and personalized medicine. Our Chief Strategy Officer Nathan Buchbinder weighs in on the growing convergence of labs and biopharma, and why pathology is emerging as a critical foundation for high-value evidence generation.